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Abstract
Oral and fecal microbial biomarkers have previously been associated with cardiometabolic
(CM) risk, however, no comprehensive attempt has been made to explore this association
in minority populations or across different geographic regions. We characterized gut- and
oral-associated microbiota and CM risk in 655 participants of African-origin, aged 25–45,
from Ghana, South Africa, Jamaica, and the United States (US). CM risk was classified
using the CM risk cut-points for elevated waist circumference, elevated blood pressure and
elevated fasted blood glucose, low high-density lipoprotein (HDL), and elevated triglycer-
ides. Gut-associated bacterial alpha diversity negatively correlated with elevated blood
pressure and elevated fasted blood glucose. Similarly, gut bacterial beta diversity was also
significantly differentiated by waist circumference, blood pressure, triglyceridemia and HDL-
cholesterolemia. Notably, differences in inter- and intra-personal gut microbial diversity
were geographic-region specific. Participants meeting the cut-points for 3 out of the 5 CM
risk factors were significantly more enriched with Lachnospiraceae, and were significantly
depleted of Clostridiaceae, Peptostreptococcaceae, and Prevotella. The predicted relative
proportions of the genes involved in the pathways for lipopolysaccharides (LPS) and buty-
rate synthesis were also significantly differentiated by the CM risk phenotype, whereby
genes involved in the butyrate synthesis via lysine, glutarate and 4-aminobutyrate/succinate
pathways and LPS synthesis pathway were enriched in participants with greater CM risk.
Furthermore, inter-individual oral microbiota diversity was also significantly associated with
the CM risk factors, and oral-associated Streptococcus, Prevotella, and Veillonella were
enriched in participants with 3 out of the 5 CM risk factors. We demonstrate that in a diverse
PLOS ONE | https://doi.org/10.1371/journal.pone.0215262 July 24, 2019 1 / 24
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Fei N, Bernabe´ BP, Lie L, Baghdan D,
Bedu-Addo K, Plange-Rhule J, et al. (2019) The
human microbiota is associated with
cardiometabolic risk across the epidemiologic
transition. PLoS ONE 14(7): e0215262. https://doi.
org/10.1371/journal.pone.0215262
Editor: Juan J. Loor, University of Illinois, UNITED
STATES
Received: March 26, 2019
Accepted: June 4, 2019
Published: July 24, 2019
Copyright: © 2019 Fei et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
Data Availability Statement: All 16S rRNA
sequences and sample metadata are publicly
available via the QIITA platform under study ID
11888 (https://qiita.ucsd.edu/study/description/
11888) and in EBI under accession no.ERP115612
(Study: PRJEB32880).
Funding: The current work is funded in part by the
National Institutes of Health R01DK080763, and
R01DK090360 to AL, and R01DK111848 to LRD.
BTL is supported by the National Institutes of
Health under award number, R01DK104927-01A1
cohort of African-origin adults, CM risk is significantly associated with reduced microbial
diversity, and the enrichment of specific bacterial taxa and predicted functional traits in both
gut and oral environments. As well as providing new insights into the associations between
the gut and oral microbiota and CM risk, this study also highlights the potential for novel ther-
apeutic discoveries which target the oral and gut microbiota in CM risk.
Introduction
Metabolic syndrome and cardiometabolic (CM) risk are associated with increased morbidity
and mortality[1–3], and includes five risk factors: visceral obesity, elevated fasted blood glu-
cose and elevated blood pressure, decreased high density lipoprotein (HDL) cholesterol,
hypertriglyceridemia [4]. In the US, as many as 35% of all US adults present with CM risk [5],
when defined using the “Adult Treatment Panel criteria”[6]. Between 1988 and 2012, the
greatest increase in the prevalence of CM disease was seen among black men, estimated to be
currently around 55%, and rose by 41% among black women [5]. There is increasing evidence
that the composition and metabolic function of the gut microbiota correlate with the progres-
sion and pathogenesis of CM disease, although the causality remains unclear [7].
One of the hallmarks of CM-related disease is the concomitant presence of low-grade sys-
temic inflammation [8]. Likewise, reduced intestinal bacterial diversity has also been reported
in conditions with chronic inflammation and CM risk, with effects on the immune system [9,
10]. The relative abundance of specific bacterial taxa has been shown to differ between individ-
uals with CM risk to healthy participants. For instance, individuals with obesity, diabetes and
cardiovascular disease, often have a significant reduction in fecal-associated short-chain fatty
acid (SCFA)-synthesizing bacteria such as Bifidobacteria, Roseburia, Faecalibacterium praus-
nitzii and Akkermansia muciniphilia [11–13]. All of these microorganisms have been shown to
exhibit anti-inflammatory effects [13–16]. Potential opportunistic pathogens, such as Staphylo-
coccus aureus and those from the family Enterobacteriaceae, are often enriched in the stools of
individuals with CM risk [17, 18]. It has been suggested that these pro-inflammatory taxa con-
tributes to the evolution of CM risk [17, 18].
There are several metabolic mechanisms through which the gut microbiota may contribute
to the CM risk. Lipopolysaccharide (LPS) is a known precursor for the development of obesity
and insulin resistance[19, 20] and an increase in the relative proportion of the bacteria that
produce LPS in the gut has been associated with elevated systemic LPS concentration, likely
resulting in high inflammation. Strong evidence for the role of LPS and TLR4 signaling in the
development of atherosclerotic lesions has been shown, with the gut microbiota considered
drivers of these atherosclerotic lesion formations [21, 22]. in atherogenesis Trimethylamine N-
oxide (TMAO), which derived from microbial trimethylamine metabolism, is also increased in
the stool of individuals with elevated CM risk [23, 24], although some find the inverse to be
true [25] and one study found an inverse association with cardiac death in African Americans
[26]. Similarly, SCFAs such as propionate, acetate and butyrate produced by bacterial fermen-
tation of indigestible fibers, are known to regulate host energy intake, expenditure and storage,
decreases their concentrations have been associated with elevated CM risk [27, 28]. Finally,
specific gut bacteria have also been associated with altered bile acid composition, which also
seem to play an important role in diabetes, obesity, non-alcoholic fatty liver disease and other
metabolic diseases via the farnesoid X receptor (FXR) and G protein-coupled bile acid receptor
(GPCR) signaling pathway [29–31]. These metabolic pathways represent mechanisms through
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which the gut microbiota may influence CM risk, and by which they might also serve as poten-
tial therapeutic targets for treating elevated CM risk.
Emerging data suggests that the oral microbiota may also be linked to elevated CM risk
[32–34]. Oral bacteria, especially potential pro-inflammatory pathogens like Pseudomonas and
Enterobacter, have been detected in human atherosclerotic plaques, associated with CM risk
[33, 35]. Hence, systemic inflammation triggered by oral pathogens may be an important com-
ponent in the pathogenesis of systemic disease [32, 36]. However, to date, it is unclear whether
there is an association between the oral and gut microbiota and elevated CM risk, and whether
the oral microbiota exhibits similar associations as gut microbiota does with CM risk. If this is
the case, then, the oral microbiota, which is substantially more convenient to collect, may be a
proxy to determine gut microbiota-derived associations that may have a more specific direct
mechanistic association with elevated CM risk. However, a lack of large-scale cohort studies
limits our interpretation of CM risk-microbiota associations, particularly across diverse
human populations.
In this study, we leveraged African-origin participants enrolled in the “Modeling the Epide-
miologic Transition Study” (METS) [37] cohort to determine the association between the gut
(stool-derived) and oral (saliva-derived) microbiota and elevated CM risk. We characterized
the gut- and oral-associated microbiota and indices of CM risk in 655 participants of African-
origin, aged 25–45, from Ghana, South Africa, Jamaica, and the United States (US). The cen-
tral hypothesis is that the oral microbial composition is associated with the gut microbial com-
position, and that both are associated with elevated CM risk in blacks.
Methods
Study participants
Participant selection. Previously, 2,506 African-origin adults (25-45yrs) were enrolled in
METS between January 2010 and December 2011 and followed on a yearly basis. A detailed
description of the METS protocol has previously been published [37]. For the current study,
fecal samples from 655 men and women from Ghana (N = 196), South Africa (N = 176),
Jamaica (N = 92) and the US (N = 191) were collected in 2014. In addition, 620 of them also
supplied saliva samples. Participants were excluded from the original study if they self-
reported an infectious disease, including HIV-positive individuals (South Africa), pregnant or
lactating women, and unable to participate in normal physical activities [37]. METS was
approved by the Institutional Review Board of Loyola University Chicago, IL, US; the Com-
mittee on Human Research Publication and Ethics of Kwame Nkrumah University of Science
and Technology, Kumasi, Ghana; the Research Ethics Committee of the University of Cape
Town, South Africa; the Board for Ethics and Clinical Research of the University of Lausanne,
Switzerland; and the Ethics Committee of the University of the West Indies, Kingston,
Jamaica. All study procedures were explained to participants in their native languages, and
participants provided written informed consent after being given the opportunity to ask any
questions.
Lifestyle and biochemical measurements. All measurements were made at research clin-
ics located in the respective communities. Weight and height were measured with participants
wearing light clothing, and no shoes. Participants were asked to provide an early morning
fecal sample, using a standard collection kit (EasySampler stool collection kit, Alpco, NH) at
their home. Fecal samples were immediately brought to the site clinics and stored at -80˚C.
The same fecal sample collection procedure was carried out at all the research sites. Partici-
pants were requested to fast from 8 pm in the evening prior to the clinic examination, during
Human gut microbiota and cardiometabolic risk
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which fasting capillary glucose concentrations were determined using finger stick (Accu-check
Aviva, Roche).
Cardiometabolic risk
We defined CM risk using the National Cholesterol Education Program’s Adult Treatment
Panel III NCEP/ ATP III criteria for cardiometabolic disease [6]. These 5 risk factors include:
1) waist circumference >102 cm in males and >88 cm in females; 2) elevated blood pressure
(�130/85 mm Hg), or receiving treatment; 3) hypertriglyceridemia (� 150 mg/dL), or receiv-
ing lipid-lowering treatment; 4) low high-density lipoprotein (HDL) cholesterol (<40 mg/dL
in males and<50 mg/dL in females), or receiving lipid-lowering treatment; and 5) elevated
fasting plasma glucose (� 110 mg/dL) or receiving glucose-lowering treatment.
DNA isolation and 16S ribosomal RNA (rRNA) gene sequencing
Microbial genomic DNA was extracted from the human stool samples using the DNeasy
PowerSoil DNA Isolation Kit (Qiagen). The V4 region of 16S rRNA gene was amplified and
sequenced using the Illumina MiSeq platform [38]. The primers used for amplification (515F-
806R) contain adapters for MiSeq sequencing and single-end barcodes allowing pooling and
direct sequencing of PCR products [39].
16S rRNA gene pyrosequencing data preprocessing and analysis
Raw sequences were pre-processed, quality filtered and analyzed using the next-generation
microbiome bioinformatics platform (QIIME2 version 2018.6 pipeline) according to the develop-
er’s suggestion [40, 41]. We used the DADA2 algorithm [42], a software package wrapped in
QIIME2, to identify exact sequence variants (ESVs). Quality control, filtering low quality regions
of the sequences, identification and removal of chimera sequences, merging paired-end reads,
which yielded the ESV feature table (ESV table). Alpha and beta-diversity analyses were per-
formed in R using the phyloseq package [43]. Alpha diversity was calculated by Shannon’s diver-
sity index, observed OTUs, and Chao1 diversity [44]. Results were adjusted for BMI, age, sex and
country. Principal coordinate analysis (PCoA) was performed based on weighted and unweighted
UniFrac distances, a method for computing differences between microbial communities based
on phylogenetic information [45]. Weighted UniFranc considered both ESVs presence and
absence and abundance distances, and unweighted UniFrac only considered ESVs presence. Per-
mutational multivariate analysis of variance (PERMANOVA, R function adonis (vegan, 999 per-
mutations)) was used to analyze statistical differences in beta diversity[46]. Benjamini–Hochberg
false discovery rate (fdr) correction was used to correct for multiple hypothesis testing [47].
The contribution of CM risk factors and environmental factors (sex, age, BMI, sleep, smoke
and alcohol consumption) to the overall weighted and unweighted UniFrac dissimilarities in
gut and oral microbiota composition was also assessed using PERMANOVA (R function ado-
nis (vegan), 999 permutations), which decomposes the dissimilarity matrix into ‘variance’
explained by each covariate. The obtained R2 gives the proportion of variability observed in
the entire dissimilarity matrix that can be independently attributed to the studied variables.
For taxonomic comparisons, relative abundances based on all obtained reads were used.
We used the QIIME2 plugin “q2-feature-classifier” and the Naïve Bayes classifier [48] that was
trained on the metagenome annotation package Greengenes13.8 [49] 99% operational taxo-
nomic units (OTUs) full-length sequences to obtain the taxonomy for each ESV. Significantly
differential ESVs were determined using the statistical framework called analysis of composi-
tion of microbiomes (ANCOM) [42] for two group comparisons. FDR correction was used to
correct for multiple hypothesis testing. Results were adjusted for BMI, age, sex and country.
Human gut microbiota and cardiometabolic risk
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A two-side Mantel test using Spearman correlation coefficients (999 permutations) was
applied to identify the correlation between the beta diversity of the oral and the gut microbiota,
with both unweighted and weighted UniFrac distance matrices in software R with the function
“mantel.test” [50].
To test for correlations between oral microbiota and the Shannon index or ESVs, which
their relative abundances was greater than 1% and are also significantly correlated with CM
risk in gut microbiota, random forest regression and generalized linear models (GLM) were
performed. Random forest regression was done with 1,000 regression trees based on 10-fold
cross-validation and performed with QIIME2 plugin “qiime sample-classifier regress-samples”
and the Random Forest regressor in the R programming environment. A randomly drawn
80% of samples were used for model training and the remaining 20% were used for validation.
Metagenome functional predictions of the microbial pathways
We used Piphillin an algorithm to predict the functional profiles of the microbiome [51].
Briefly, this algorithm uses direct nearest-neighbor matching between 16S rRNA gene
sequencing datasets and microbial genomic databases to infer the metagenomic content of the
samples. Gene prediction was performed on ESVs table using online Piphillin (http://
secondgenome.com/Piphillin), with KEGG database version 2017 and 97% identity cut-off.
Predicted gene content and gene copy numbers within each genome were retrieved and classi-
fied in terms of the ezymes code by each gene as KEGG orthology (KOs) [52]. Results were
adjusted for BMI, age, sex and country. Statistical analyses were performed in R. Student’s t-
test (normally distributed) or Mann-Whitney U test (not normally distributed) was used for to
detect differentially abundant KOs between two groups. FDR correction was used to correct
for multiple hypothesis testing.
Results
Participant characteristics
Previously 2,506 adults from Ghana, South Africa, Jamaica, The Seychelles, and US were
recruited in 2009, and prospectively followed on an annual basis in METS [37]. The current
study included a subsample of 655 participants, of which 196 were Ghanaian, 176 were South
African, 92 were Jamaican, and 191 were from the US (Table 1). Approximately 60% of the
participants were women. The average age among all the participants was 34.9 ± 6.4 years, and
participants from South Africa and Jamaica were significantly younger than US participants (p
<0.001 and p = 0.016, respectively). Men and women from Ghana, South Africa and Jamaica
weighed significantly less (p<0.001) than their US counterparts (63.2 ± 12.0, 76.2 ± 20.5, and
80.0 ± 21.1 kg, respectively), and there were significantly more US men and women that were
overweight and obese (81.3%, p<0.001 for all) compared with the other cohorts (i.e., Ghana,
33.2%; South Africa, 55.7%; Jamaica 65.2%) (Table 1). Americans also slept the least number
of nightly hours (6.7 ± 1.4 hrs) compared to Ghanaians (7.9 ± 1.4 hrs, p<0.001), Jamaicans
(7.3 ± 2.1 hrs, p<0.033), and South Africans (10.5 ± 1.7 hrs, p<0.001), and reported signifi-
cantly higher prevalences of cigarette smoking (37.7%, p<0.001), and alcohol consumption
(84.3%, p<0.001) compared to the other 3 sites, after adjusting for age, sex and BMI (Table 1).
Cardiometabolic risk
We used the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP/
ATP III) criteria for metabolic syndrome [6] to indicate CM risk, and as follows; waist circum-
ference>102 cm in men and>88 cm in females; elevated blood pressure (�130/85 mm Hg),
Human gut microbiota and cardiometabolic risk
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or receiving treatment for hypertension; hypertriglyceridemia (�150 mg/dL) or receiving
treatment; low high-density lipoprotein (HDL) cholesterol (<40 mg/dL in males and<50 mg/
dL in females), or receiving treatment; and elevated fasting plasma glucose (�110 mg/dL) or
receiving treatment for type 2 diabetes. Individuals with a BMI�25 kg/m2 were classified as
overweight, and�30 kg/m2 were categorized as obese [53]. For the purpose of our analysis, we
dichotomized CM risk creating a CM risk phenotype, whereby those with elevated CM risk
had at least 3 of the five CM risk factors, compared to those with 2 or less. Because the Jamai-
can participants were missing HDL and triglyceride concentration measures in blood, they
were excluded from the overall CM risk analysis. This resulted in a total of 563 participants
with complete CM risk data. Overall, 46 of these 563 participants (8.2%) presented with ele-
vated CM risk. Compared to the US participants (14.7%), the prevalence of elevated CM risk
was significantly lower among the Ghanaians (1.5%, p<0.001), and trended lower among the
South Africans (8.5%, p = 0.09) (Table 2).
Gut-derived bacterial diversity associates with country of origin and CM
risk factors
The associations between the gut-derived microbial diversity measured by 16S rRNA amplicon
sequences using exact sequence variants (ESVs) and indices of elevated CM risk were calcu-
lated across the four cohorts. All analyses were adjusted for age, sex and BMI. Gut bacterial
alpha diversity (intrapersonal gut diversity, measured by Shannon and Chao1 indexes)[44]
was significantly greater among the Ghanaians and South Africans, compared to the US partic-
ipants (p<0.001; Fig 1, S1 Fig). The Shannon index, which incorporates both the richness
and evenness of the community, was lower among participants with elevated blood pressure
from South Africa (p<0.05) and Ghana (p<0.01) but showed no significant relationship
among the US participants or the Jamaicans (Fig 1, S2 Fig). Elevated fasted blood glucose was
significantly associated with lower alpha diversity, but only among the Jamaicans (p<0.05; Fig
1, S2 Fig). Individuals with elevated waist circumference, triglyceride concentration and HDL
Table 1. Participant characteristics by site. The US is the reference site.
Ghana South Africa Jamaica US Overall
N N = 196 N = 176 N = 92 N = 191 N = 655
Age (y) 35.8 ± 6.6 33.3 ± 5.9� 33.9 ± 6.2� 36.0 ± 6.3 34.9 ± 6.4
Weight (kg) 63.2 ± 12.0�� 76.2 ± 20.5�� 80.0 ± 21.1�� 94.2 ± 25.0 78.1 ± 23.3
Height (cm) 161.7± 7.6�� 163.7 ± 7.7�� 166.8 ± 10.9�� 169.6 ± 8.4 165.2 ±9.0
BMI (kg/m2) 24.3 ± 5.0�� 28.7 ± 8.2�� 29.1 ± 8.9�� 32.8 ± 8.8 28.6 ±8.4
Normal weight (BMI<25 kg/m2), N, % 131, 66.8%�� 78, 44.3%�� 32, 34.8%�� 36, 18.9% 277, 42.3%
Overweight (BMI�25 kg/m2-<30 kg/m2) 41, 20.9% 28, 15.9%�� 28, 30.4% 52, 27.2% 149, 22.8%
Obese (BMI�30 kg/m2) 24, 12.2%�� 70, 39.8%�� 32, 34.8%�� 103, 53.9% 229, 35.0%
Fat-free mass (kg) 44.3 ± 7.4�� 44.6 ± 7.2�� - 55.1 ± 11.2 48.1 ± 10.2
Fat mass (kg) 19.0 ± 9.2�� 31.7 ± 16.2�� - 39.3 ± 18.4 29.9 ± 17.3
% Body fat 29.2 ± 9.84�� 39.3 ± 11.0 - 39.9 ± 10.8 36.0 ± 11.6
Sleep hours (hrs/night) ¥ 7.9 ± 1.4�� 10.5 ± 1.7�� 7.3± 2.1� 6.7 ± 1.4 8.2 ± 2.2
Smokers¥ 4, 2.0%�� 48, 27.3%�� 10, 10.9%�� 72, 37.7% 134, 20.5%
Drinkers¥ 59, 30.6%�� 75, 42.9%�� - 161, 84.3% 295, 52.8%
�p<0.05
��p<0.01 compared to US.
¥Adjusted for age, sex and BMI
https://doi.org/10.1371/journal.pone.0215262.t001
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levels showed no significant associations for gut microbial alpha diversity (adjusted for age, sex
and BMI, p>0.05, S2 Fig). These results suggest that decreased gut microbial alpha diversity is
associated some of the CM risk factors (i.e., elevated blood pressure and elevated fasting blood
glucose), however, these associations are country specific.
Gut bacterial beta diversity was significantly different between countries [false discovery
rate (fdr)-corrected p<0.01; S3 Fig]. Therefore, as with alpha diversity, we derived associa-
tions of beta diversity against CM risk within each country independently (S4 and S5 Figs).
Weighted and unweighted UniFrac distances, which compute differences between microbial
communities based on phylogenetic information[45], were significantly different between
high and low waist circumference, but only among the South Africans (fdr-corrected p<0.05)
and Ghanaians (fdr-corrected p<0.01). The same was true for elevated blood pressure,
whereby weighted UniFrac was significantly different among the South Africans (fdr-corrected
p<0.05) and Ghanaians (fdr-corrected p<0.05), but interestingly, unweighted UniFrac was
only significantly different in the South Africa cohort (fdr-corrected p <0.05). This might sug-
gest that the differences seen in the South Africans may be in part due to differences in the
abundance of rare bacterial taxa, while in Ghana the differences may be due to more abundant
bacterial taxa in the fecal samples. Similarly, for triglyceride concentrations, only weighted
UniFrac was significantly different and only among the South Africans (fdr-corrected p
<0.05), while for HDL concentrations only weighted UniFrac was significantly different
among US participants (fdr-corrected p<0.05). Hyperglycemia was not significantly corre-
lated with beta diversity in any of the cohorts. These results suggest that gut microbial structure
is significantly associated with individual CM risk factors, and that these associations are geo-
graphically dependent, given that the contribution of the abundant versus rare bacterial taxa
varied with country of origin. Taken together, contributions of CM risk as well as environmen-
tal factors, including country of origin, result in inter-individual dissimilarities in the gut
microbial composition (S1 Table).
Table 2. Cardiometabolic risk by site, and overall. The US is the reference site, and comparisons are adjusted for age, sex and BMI.
Ghana South Africa Jamaica United States Overall
N = 196 N = 176 N = 92 N = 191 N = 655
Fasted plasma glucose (mg/dL) 100.7 ± 12.2 83.3 ± 18.1�� 99.6 ± 15.5 106.2 ± 40.4 97.5 ± 26.8
Elevated fasted plasma glucose, N, % 2, 1.0%�� 8, 4.6%�� 18, 19.6% 45, 23.9% 73, 11.2%
Systolic blood pressure (mmHg) 112.9 ± 13.5�� 124.4 ± 20.5� 112.7 ± 12.5�� 123.3 ± 17.6 119.0 ± 17.5
Diastolic blood pressure (mmHg) 66.6 ± 11.0�� 79.4 ± 12.8 72.0 ± 34.0�� 80.5 ± 13.1 74.9 ± 18.1
Elevated blood pressure, N, % 6, 3.1%�� 26, 14.8% 1, 1.1%� 25, 13.1% 58, 8.9
Triglycerides (mg/dL) 82.1 ± 36.5 88.2 ± 55.1 - 98.5 ± 62.1 89.5 ± 52.5
Hypertriglyceridemia, N, % (N = 563) 12, 6.2% 16, 9.1% - 29, 15.7% 57, 10.3%
HDL-cholesterol (mg/dL) 46.1 ± 13.6�� 49.9 ± 15.0� - 52.1 ± 15.1 49.3 ± 14.7
Low HDL-cholesterol, N, % N = 563 104, 53.6%�� 79, 45.4%� - 64, 34.8% 247, 44.8%
LDL-cholesterol (mg/dL) 100.7 ± 29.1 92.9 ± 32.6�� - 110.1 ± 35.5 101.4 ± 33.1
Total cholesterol (mg/dL) 163.3 ± 34.3�� 160.1 ± 36.1�� - 183.0 ± 38.6 168.9 ± 37.7
High waist circumference N, % N = 563 37, 18.9%�� 78, 44.3%�� 37, 40.2%�� 116, 60.7 268, 40.9%
Cardiometabolic disease N, % N = 563 3, 1.5%� 15, 8.5% - 28, 14.7 46, 8.2%
Cardiometabolic risk is defined by three out of five risk factors: waist circumference >102 cm in males and >88 cm in females; elevated blood pressure (� 130/85 mm
Hg), or receiving treatment; hypertriglyceridemia (� 150 mg/dL), or receiving treatment; low HDL (<40 mg/dL in males and <50 mg/dL in females), or receiving
treatment; and elevated fasting plasma glucose (� 110 mg/dL) or receiving treatment.
�p<0.05
��p<0.01 compared to US.
https://doi.org/10.1371/journal.pone.0215262.t002
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Fig 1. Gut bacterial alpha diversity associations with cardiometabolic risk factors (adjusted for age, sex and BMI, only significant associated were shown here). a)
Alpha diversity (Shannon index) in the four study sites (USA, RSA, Ghana and Jamaica); b) association with hypertension in RSA; c); association with elevated fasting
blood glucose in Jamaica; d); association with hypertension in Ghana. � p<0.05; �� p<0.01.
https://doi.org/10.1371/journal.pone.0215262.g001
Human gut microbiota and cardiometabolic risk
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Gut microbial structure and function correlate with CM risk phenotype
We next investigated whether the gut microbiota correlated with an elevated CM risk pheno-
type in the participants from USA, Ghana and South Africa. Jamaican’s were excluded from
this analysis due to missing lipid data, and analyses were adjusted for age, sex and BMI. Partici-
pants with elevated CM risk phenotype (at least 3 risk factors) had significantly lower fecal
alpha diversity (measured by Shannon index), compared to those without elevated CM risk (p
<0.001; Fig 2A). Furthermore, weighted and unweighted UniFrac distances were significantly
different between the two CM risk phenotypes (fdr-corrected p< 0.05; Fig 2B and 2C). We
were able to identify the fecal bacterial ESVs which had significantly different abundance as a
function of elevated CM risk. For these ESVs with a relative abundance�1% in at least one
group (adjusted for country, sex, age and BMI), participants with elevated CM risk were signif-
icantly enriched with 2 bacterial ESVs annotated to family Lachnospiraceae and genus Bacter-
oides, while participants without elevated CM risk had were enriched in 3 bacterial ESVs
annotated to family Clostridiaceae, Peptostreptococcaceae, and genus Prevotella (fdr-corrected
p<0.05; Fig 2D).
Fig 2. Gut bacterial structure and function correlates with cardiometabolic (CM) risk phenotype. (a), Alpha diversity analysis (Shannon Index) from 16S rRNA gene
sequence data of gut microbiota against CM risk; (b-c), Principal coordinate analyses (PCoA) of weighted (a) and unweighted (b) UniFrac distance of gut microbiota
composition against CM risk (fdr-corrected p<0.01); (d), Specific gut bacterial taxa are differentially abundant (in relative terms) between study sites with and without
elevated CM risk (only significantly differential exact sequence variants (ESVs) with relative abundance� 1% in at least one group shown. Data shown are means ± S.E.
M.; p(fdr-corrected)<0.05); (e), Relative abundance of the genes involved in the four different pathways for butyrate synthesis against CM risk of gut microbiota across
all study sites. (Data shown are means of percentages ± S.E.M. p(fdr-corrected)< 0.05). CMD means CM risk defined as at least 3 CM risk factors from five: waist
circumference, elevated blood pressure, elevated blood fasting glucose, elevated triglyceride and low HDL concentration in USA, RSA, and Ghana ��� p< 0.001. false
discovery rate.
https://doi.org/10.1371/journal.pone.0215262.g002
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Specific gut bacterial taxa were also associated with individual CM risk across the entire
cohort (adjusted for country, age, sex and BMI, S6 Fig and S2 Table) or when stratified by sex
(adjusted for country, age and BMI, S6 Fig and S2 Table). We found that the gut microbial
taxa level was profoundly altered in participants for each of the CM risk factors. For example,
among participants with an elevated waist circumference, hyperglyceridemia, elevated blood
pressure or low HDL concentration, there were a significant enrichment of bacterial ESVs
annotated to genera belonging to family Lachnospiraceae, Enterobacteriaceae and Clostridia-
ceae; genera Streptococcus, Coprococcus and Blautia (fdr-corrected p <0.05). Conversely,
bacterial ESVs annotated to genus Prevotella (family Prevotellaceae), and family Enterobacter-
iaceae, Clostridiaceae, and Peptostreptococcaceae were also significantly enriched among par-
ticipants without CM risk (fdr-corrected p<0.05; S1 File). As expected, there were also several
gut bacterial taxa that were differentially abundant between each country and each CM risk
factor (S7 Fig and S2 Table).
The 16S rRNA amplicon data was used to predict gene abundance using Piphillin[51] to
establish differences in the gut microbial metabolic potential in several well-known pathways
associated with elevated CM risk, such as LPS biosynthesis, SCFA metabolism, TMA N-oxide
(TMAO) biosynthesis, and genes associated with secondary bile acid biosynthesis. No statisti-
cally significant differences in the proportion of genes encoding components of TMA N-oxide
(TMAO) biosynthesis, LPS biosynthesis, and secondary bile acid biosynthesis were observed
among participants who had an elevated CM risk phenotype (at least 3 risk factors), compared
to those without CM risk (adjusted for country, sex, BMI and age, p>0.05). However, the rela-
tive abundance of the genes involved in the four different pathways for butyrate synthesis
showed that several genes that encode for enoyl-CoA hydratase enzymes (K01692, K01782,
K01825) in the acetyl-CoA pathway were enriched in participants without elevated CM risk;
while, crotonase (K01715) and β-hydroxybutyryl-CoA dehydrogenase (K00074) in the acetyl-
CoA pathway were enriched in participants with elevated CM risk. Notably, the abundance of
predictive genes that encode for glutaconyl-CoA decarboxylase (α, β subunits) (K01615) in the
glutarate pathway and the 4-hydroxybutyryl-CoA dehydratase (K14534) in the 4-aminobyty-
rate/succinate pathway were enriched in participants with elevated CM risk (adjusted for
country, sex, age and BMI, fdr-corrected p< 0.05; Fig 2D).
We also explored whether gut bacterial functions were associated with each of the 5 individ-
ual CM risk factor within each of the countries. Gut microbial predicted genes involved in LPS
and SCFA biosynthesis pathways showed that genes involved in the butyrate synthesis via
lysine, glutarate and 4-aminobutyrate/succinate pathways and LPS synthesis pathway were dif-
ferentially enriched among the cohort with an elevated individual CM risk factor (S8–S11
Figs). Specifically, predicted genes involved in LPS biosynthesis pathways were enriched
among participants with an elevated waist circumference in Ghana and US; participants with
an elevated blood pressure in Ghana and Jamaica; participants with an elevated fasted blood
glucose in Jamaica and the US, and those with low HDL in South Africa and the US. As the
butyrate synthesis via lysine, glutarate and 4-aminobutyrate/succinate pathways, predicted
genes involved in the glutarate pathway were significantly enriched in participants with a high
waist circumference in South Africa and Ghana, and also participants with low HDL concen-
trations in the US and South Africa; predicted genes involved in the lysine pathway were
enriched in participants with elevated blood pressure in Ghana; and predicted genes involved
in the 4-aminobytyrate/ succinate pathway in South Africans were significantly associated
with low HDL concentrations (see detail in S1 File; S8–S11 Figs).
Generalized linear models (GLM) were applied to explore the associations between alpha
diversity, bacterial taxa and predicted functional genes and total CM risk (captured as the sum
of CM risk factors in each participant). For instance, there was a significant positive correlation
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between the proportion of KEGG ID K01615 in the glutarate pathway and K14534 in the
4-aminobytyrate/succinate pathway and total CM risk score (i.e. a z-score transformation to
generate continuous discrete measurements, controlling for country, age, sex, and BMI, p
<0.05, see methods for more details). However, there were no significant associations between
diversity or differential bacterial taxa and total CM risk (p>0.05). To explore whether the gut
microbiota predicted elevated CM risk (three out of the five risk factors), random forest regres-
sion was used to determine the gut bacterial ESVs against the total CM risk (z-score trans-
formed) pooling the 3 sites with CM risk data. Elevated CM risk could be predicted by gut-
associated ESVs and explained almost 15% of the elevated CM risk variance among those with
CM risk data.
Oral-associated bacterial diversity associates with country of origin and
CM risk factors
On the other hand, oral microbiota diversity was associated with the country of origin, but not
with the individual CM risk factors. Shannon diversity was significantly greater among the
Ghanaians compared to the US participants (adjusted for age, sex and BMI, p <0.05; S12 Fig).
As oral microbial alpha diversity was significantly different between countries, we correlated
CM risk against alpha diversity for each country independently and found that none of the
CM risk factors were significantly associated with oral microbial alpha diversity (p>0.05, S13
Fig). However, oral microbial beta diversity was significantly different between participants
from different countries (fdr-corrected p<0.01, S14 Fig), and therefore, tests of association
were performed separately for each country. In the US sample, weighted UniFrac distance was
significantly different between individuals with either high and normal waist circumference
(fdr-corrected p<0.01) and similarly, between participants with either elevated or normal glu-
cose concentrations (fdr-corrected p<0.05, S15 Fig). Unweighted UniFrac distances were sig-
nificantly different between individuals with either elevated and normal waist circumference
in the US (fdr-corrected p� 0.01), Ghana (fdr-corrected p<0.05), and South Africa (fdr-cor-
rected p<0.05) (S16 Fig). In the US alone, unweighted UniFrac was significantly different by
HDL risk (fdr-corrected p<0.05) (S16 Fig). Therefore, oral beta diversity, and hence micro-
bial structure, was significantly associated with several CM risk factors, but similarly differed
by country, suggesting that environmental factors are critical for inter-individual dissimilari-
ties in oral microbial composition (S3 Table).
Oral-associated bacterial community structure correlates with the elevated
CM risk phenotype
We next investigated whether the oral microbiota correlated with the elevated CM risk pheno-
type (3 out of five risk factors) and CM risk score in the US, Ghanaian and South African par-
ticipants. Alpha diversity was not significantly different between low and elevated CM risk
(adjusted for age, sex and BMI, p(fdr-corrected) <0.05, S17 Fig). However, both weighted and
unweighted UniFrac distance were significantly differentiated by CM risk (fdr-corrected p
<0.01, Fig 3A and 3B). The differential taxa analysis (with relative abundance�1% in at least
one group) showed that participants with elevated CM risk had a significant enrichment of 4
oral-bacterial ESVs annotated to the genera Prevotella, Veillonella, and Streptococcus; while
participants without elevated CM risk had a significant enrichment of 5 bacterial ESVs anno-
tated to genus Haemophilus, Neisseria, Fusobacterium (adjusted for country, sex, BMI and age,
p(fdr-corrected) <0.05; Fig 3C). Several oral-bacterial ESVs annotated to the genus Rothia
presented opposite behaviors (i.e., some were enriched, and some were depleted in participants
with elevated CM risk compared with low CM risk)
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At a more granular level, specific oral bacterial taxa were also associated with each CM risk
factor across the entire cohort (adjusted for country, age, sex and BMI; S18 Fig and S4 Table)
or when stratified by sex (adjusted for country, BMI and age; S18 Fig and S4 Table), sepa-
rately. The results indicate that the oral microbiota of participants who have greater CM risk,
e.g. a higher waist circumference, elevated blood pressure or low HDL concentration, are sig-
nificantly enriched for potentially pro-inflammatory taxa, including Streptococcus, Prevotella,
Fig 3. Oral-associated bacterial structure correlates with CM risk phenotype. (a-b), Principal coordinate analyses (PCoA) of weighted (a) and unweighted (b)
UniFrac distance of oral microbiota composition against CM risk (fdr-corrected p<0.01). (c), Specific oral bacterial taxa are differentially abundant (in relative terms)
between study sites with and without CM risk (only significantly differential exact sequence variants (ESVs) with relative abundance� 1% in at least one group shown.
Data shown are mean± S.E.M. p(fdr-corrected)< 0.05). CMD means CM risk, including at least 3 CM risk factors of waist circumference, elevated blood pressure,
elevated blood fasting glucose, high triglyceridemia and low HDL-cholesterolemia in USA, RSA, and Ghana. fdr, false discovery rate.
https://doi.org/10.1371/journal.pone.0215262.g003
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and Veillonella (fdr-corrected p<0.05; S1 File). There were also specific oral bacteria that
were differentially abundant between each country by each CM risk factor (fdr-corrected p
<0.05; S1 File; S19 Fig and S2 Table).
To determine whether the taxa could identify participants with elevated CM risk, we once
again used GLM to determine the association between the differential proportional oral bacte-
rial taxa and total CM risk (sum of the number of CM risk factors for each participant). There
was a significantly positive association between the proportion of a Streptococcus ESV and
total CM risk (z-score transformation), controlling for country, age, and sex p<0.05). To test
whether the oral microbiota can identify participants with the elevated CM risk phenotype,
random forest regression was used to examine the association of oral bacterial ESVs against
CM risk (z-score transformed). Among participants with elevated CM risk, oral bacterial
ESVs, accounted for almost 8% of the variance.
Correlation of beta diversity between gut and oral microbiota
Finally, to explore whether the beta diversity trends seen in the oral microbiota correlated with
those in the gut microbiota, we applied a Mantel test using both unweighted and weighted
UniFrac distance matrices. Pooling all countries, there was a significant correlation with both
unweighted (r = 0.094, p = 0.001) and weighted (r = 0.082, p = 0.001) UniFrac distance
between the gut and oral microbiota (S20 and S21 Figs). However, within each country, only
the weighted UniFrac metric had a significant correlation between oral and gut microbial beta
diversity, and only among the US and South African participants (p = 0.034, r = 0.073 and
p = 0.021, r = 0.09 respectively) (S20 and S21 Figs).
Discussion
In our study of African-origin adults from Ghana, South Africa, Jamaica and the US, we per-
formed a comprehensive analysis exploring the relationship between the gut and oral micro-
biota and elevated CM risk, representing 4 geographically diverse countries spanning an
epidemiologic transition. Overall, our results provide evidence that the gut and oral microbiota
may potentially be both predictive as well as a therapeutic target for elevated CM risk, and is in
line with previous evidence that the human microbiota are associated with CM risk [54, 55].
Consistent with previous studies [9, 56], we found that the gut microbial alpha diversity
was significantly lower in participants with elevated CM risk. However, these associations are
mostly geographical and dependent on the type of CM risk factor, e.g. for elevated blood pres-
sure, the association was only found among South Africans and Ghanaians, while only Jamai-
cans had differences for elevated fasted blood glucose. Similarly, gut bacterial beta diversity
was also significantly different between participants with an elevated waist circumference, ele-
vated blood pressure, hypertriglyceridemia or low HDL concentration, compared with their
healthy counterparts. Although again, the associations differed by country, e.g. for an elevated
waist circumference, the associations were only found among the South African and Ghanaian
participants, and for low HDL concentration, only among the US participants.
Previous studies have reported conflicting results as to which specific bacterial taxa associ-
ate with CM risk factors [11–13, 17, 18]. In our study, gut bacterial ESVs annotated to family
Lachnospiraceae were significantly enriched in participants with the elevated CM risk pheno-
type, along with individual risk factors, including elevated waist circumference and hypertri-
glyceridemia. Previously, a number of studies have found that an enrichment of
Lachnospiraceae was associated with the development of obesity, insulin resistance and other
metabolic disorders [57–61]. Notably, participants with an elevated waist circumference also
showed an enrichment for the genus Streptococcus, which has previously been found to be
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enriched in some CM diseases [17]. In our study, participants with healthy waist circumfer-
ences, and blood pressure and a normal fasting blood glucose exhibited a significant enrich-
ment of the Ruminococcaceae family (S1 File), which includes several kinds of beneficial
bacteria known to be negatively correlated to metabolic disease and associated with lower CM
risk, e.g. genus Faecalibacterium [62, 63] and genus Oscillospira [64]. Similarly, gut bacterial
ESVs annotated to the Clostridiaceae and Peptostreptococcaceae families and Prevotella genus
were enriched in participants with a lower total CM risk as well as individual CM risk factors,
e.g. healthy waist circumferences and normal fasting blood glucose levels, consistent with pre-
vious research, reporting a negative association with obesity or other CM risk factors [18, 65,
66]. Although it should also be noted that there are a handful of studies that suggest that Clos-
tridiaceae and Prevotella are significantly enriched in patients with metabolic diseases [66–68].
Our predicted metagenomic functional analysis showed that participants with elevated CM
risk harbored a more pronounced inflammatory phenotype. Indeed, predicted genes involved
in LPS biosynthesis pathways were significantly enriched in participants presenting with indi-
vidual CM risk factors across diverse geographic settings. Similar findings have previously
been reported and suggest that a capacity for an increased LPS synthesis potential in the gut
microbiota of people with obesity, diabetes, symptomatic atherosclerosis, arterial thrombosis,
and other related metabolic diseases [19–22, 69]. Of note, the predicted relative proportion of
genes that encode for enzymes involved in butyrate synthesis pathway suggested that the lysine
pathway, glutarate pathway, and 4-aminobytyrate/succinate pathway were significantly
enriched in individuals with elevated CM risk and also individual risk factor. Butyrate can be
synthesized via different substrates, driven by enzymes that are produced and secreted by dif-
ferent bacteria [70]. While the most common pathway for butyrate synthesis is via pyruvate
and acetyl-coenzyme A, other less-dominant pathways include amino-acids (lysine, glutarate
and 4-aminobytyrate/succinate) as substrates via the 4-aminobutyrate pathway, which can
produce pro-inflammatory byproducts [70] and are related with obesity. Together, these
results suggest that the gut microbial metabolic functional potential of participants with ele-
vated CM risk had a marked inflammation-driving capacity, which may influence host sys-
temic inflammatory levels and may ultimately lead to the CM disease consequence.
While the impact of ethnicity on the core of gut microbiota has been demonstrated by several
studies [71, 72], exploring the impact of ethnicity and the associations between gut microbiota
and CM risk has not been performed to date. Some studies find that there is a decrease in the
gut microbial alpha-diversity that is associated with CM risk from different ethnicities, e.g. Dan-
ish obese individuals when compared to non-obese individuals9 and obese compared with lean
in a mid-western US female adolescent twin cohort study [56]. Similarly, previous studies find
that there is a shared alteration in the gut microbial composition of the individuals with elevated
CM risk and adiposity derived from different ethnicities. For example there was an adiposity-
related enrichment of Lachnospiraceae in the gut microbiota of participants enrolled in the
Twins UK cohort study[61], as well as among British obese individuals [60], and obese, Colom-
bian subjects [73] with increased cardiometabolic risk, and finally among individuals in the
midst of Westernization [74] when compared to the lean individuals, respectively. Interestingly,
the association between TMAO and cardiovascular disease has been found to be significantly
greater in whites compared to blacks [26]. In our study of African-origin adults, there was no
significant association between predicted genes involved in TMAO biosynthetic pathway and
total CM risk or individual CM risk factors, consistent with previous research, finding a negative
association between TMAO concentration and cardiac death in black participants [26].
Numerous reports have implicated a close linkage between oral infections, particularly peri-
odontitis, and several systemic diseases, e.g. atherosclerosis, type 2 diabetes mellitus, athero-
sclerotic cardiovascular disease [32–34]. In our study, we found that the oral microbial
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structure (measured by beta diversity) was associated with indices of elevated CM risk, e.g.
high waist circumference, elevated fasted blood glucose, and low HDL concentration. How-
ever, as with gut microbiota, these associations varied according to the geographic region.
There were also several ESVs significantly associated with total elevated CM risk as well as the
individual CM risk factors. For example, participants with total elevated CM risk or individual
CM risk factors, e.g. elevated waist circumference, low HDL concentration, elevated blood
pressure or hypertriglyceridemia, exhibited enriched oral bacterial ESVs annotated to genus
Streptococcus, Prevotella, or Veillonella, which were previously reported to be associated with
obesity and other cardiometabolic disease [75–78]. Systemic inflammation is an important
component of the role of oral bacteria in the pathogenesis of systemic diseases [32, 36]. Some
strains in genera Streptococcus, Prevotella, or Veillonella are opportunistic pathogens and have
been previously reported to be associated with inflammatory diseases [79–81], even though,
we also found that ESVs in genus Neisseria were higher in participants without individual CM
risk, e.g. elevated waist circumference, elevated blood pressure or hypertriglyceridemia, incon-
sistent with previous reports as described above. Importantly, we found a number of instances
whereby different ESVs of the same genus were associated with differential CM risk. For exam-
ple, different ESVs belonging to the genus Rothia were significantly enriched in the oral micro-
biota of participants both with and without elevated CM risk. While it is possible that these are
spurious relationships, it is also possible that these two unclassified Rothia strains have differ-
ent genetic makeup in non-genera conserved regions or different transcriptional and/or trans-
lational profiles in genus conserved regions associated with CM risk (e.g., distinct
immunological and/or metabolic properties) that could result in different host-associated
impact. Indeed, this may explain the conflicting results with certain studies [82]. The oral
microbiota may significantly impact the CM risk through triggering of inflammatory pro-
cesses. Consequently, an analysis of the oral microbiota can be imagined to be used as a pre-
screening test for CM risk, despite differences between the gut and oral bacterial diversity and
taxa associated with elevated CM risk. Notably, in this study, we also found a weak but signifi-
cant association between the oral and gut microbiota, within the structure and also the func-
tional taxa. Thus, it is conceivable that the oral microbiota might be used as a proxy to
determine gut-derived associations with CM risk.
Conclusions
In conclusion, our findings extend our insights into the relationship between the human
microbiota and elevated CM risk at the structural and functional level, pointing to possible
future therapeutic modalities for CM risk targeting the gut and oral microbiota. Our findings
identify previously unknown links between gut and oral microbiota alterations, and CM risk,
suggesting that gut and oral microbial composition, structure and predicted functional poten-
tial may serve as predictive biomarkers for identifying CM risk, as well as therapeutic targets.
The features of association between human microbiome and CM risk is diverse in different
populations and indicates that different interventions and potential individualized treatment
methods targeting the microbiome need to be developed to control the development of CM
risk across the world. Indeed, we are continuing our exploration of these relationships in our
large international cohort of African-origin adults spanning the epidemiologic transition [37].
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S1 Fig. Gut bacterial alpha diversity is associated with country of origin. (a-c) Alpha diver-
sity analysis (Shannon Index (a), observed OTU (b) and Chao1 (c)) from 16S rRNA gene
sequences of stool microbiota shows the differences among population from USA, RSA,
Ghana and Jamaica. USA, the United States of America; RSA, South Africa. � p< 0.05.
(TIF)
S2 Fig. Gut bacterial alpha diversity is associated with individual CM risk factors. Alpha
diversity analysis (Shannon Index) from 16S rRNA gene sequences of stool microbiota against
each CM risk factors, including waist circumference, blood pressure, blood fasting glucose, tri-
glyceride and HDL concentration in USA, RSA, Ghanaian and Jamaican populations. USA,
the United States of America; RSA, South Africa. � p< 0.05, �� p< 0.01.
(TIF)
S3 Fig. Gut bacterial beta diversity is significantly different between different countries.
Principal coordinate analyses (PCoA) of weighted (a) and unweighted (b) UniFrac distances
of stool microbiota composition in USA, RSA, Ghanaian and Jamaican populations. USA, the
United States of America; RSA, South Africa.
(TIF)
S4 Fig. Gut bacterial beta diversity based on weighted UniFrac distance is associated with
individual CM risk factors. (a-r), Principal coordinate analyses (PCoA) of weighted UniFrac
distance of stool microbiota composition against each CM risk factors, including waist circum-
ference, blood pressure, blood fasting glucose, triglyceride and HDL concentration in USA,
RSA, Ghanaian and Jamaican populations. USA, the United States of America; RSA, South
Africa.
(TIF)
S5 Fig. Gut bacterial beta diversity based on unweighted UniFrac distance is associated
individual CM risk factors. (a-r), Principal coordinate analyses (PCoA) of unweighted Uni-
Frac distance of stool microbiota composition against each CM risk factors, including waist
circumference, blood pressure, blood fasting glucose, triglyceride and HDL concentration in
USA, RSA, Ghanaian and Jamaican populations. USA, the United States of America; RSA,
South Africa.
(TIF)
S6 Fig. Specific gut bacterial exact sequences variances (ESV) are differentially abundant
between populations from all countries and against each country and individual CM risk
factor. (a-c), Waist circumference across all, male and female participants; (d-f), elevated
blood pressure across all, male and female participants; (g-h), elevated fasted blood glucose
across all and female participants; (i-j), hypertriglyceridemia across all and female participants;
(k), HDL concentration across all and female participants. Only significantly differential ESAs
with relative abundance� 1% in at least one group are shown. Data shown are mean± S.E.M.
p(fdr-corrected) <0.05. USA, the United States of America; RSA, South Africa.
(TIF)
S7 Fig. Specific gut bacterial exact sequences variances (ESV) are differentially abundant
between populations against each country and individual CM risk factor. (a), Waist cir-
cumference in Ghanaian and RSA population; (b), elevated fasting plasma glucose in Jamaican
population; (c), elevated fasting plasma glucose in RSA population; (d), elevated fasting plasma
glucose in RSA population. Only significantly differential ESAs with relative abundance� 1%
in at least one group are shown. Data shown are mean± S.E.M. p(fdr-corrected) < 0.05. USA,
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the United States of America; RSA, South Africa.
(TIF)
S8 Fig. Gut microbial predicted genes involved in LPS biosynthesis pathways against each
country and individual CM risk factor. (a), Waist circumference in Ghanaian and USA pop-
ulation; (b), elevated blood pressure in Ghanaian and Jamaican population; (c), elevated fast-
ing plasma glucose in USA and Jamaican population; (d), elevated fasting plasma glucose in
USA and RSA population. USA, the United States of America; RSA, South Africa. Only signifi-
cantly differential KOs are shown. Data shown are mean± S.E.M. p(fdr-corrected) < 0.05.
(TIF)
S9 Fig. Relative abundance of the gut microbial predicted genes involved in the four buty-
rate synthesis pathways against individual CM risk factor across all countries. Only signifi-
cantly differential KOs are shown. Data shown are mean± S.E.M. � p(fdr-corrected) <0.05.
(TIF)
S10 Fig. Gut microbial predicted genes involved in SCFA biosynthesis pathways against
each country and individual CM risk factor. (a), Waist circumference in Ghanaian and RSA
population; (b), elevated blood pressure in RSA population. ko00620, pyruvate metabolism,
ko00640, propanoate metabolism, and ko00650, butanoate metabolism. USA, the United
States of America; RSA, South Africa. Only significantly differential KOs are shown. Data
shown are mean± S.E.M. p(fdr-corrected) < 0.05.
(TIF)
S11 Fig. Relative abundance of the gut microbial predicted genes involved in the four dif-
ferent butyrate synthesis pathways against individual CM risk factor within each country.
USA, the United States of America; RSA, South Africa. Only significantly differential KOs are
shown. Data shown are mean± S.E.M. � p(fdr-corrected) < 0.05.
(TIF)
S12 Fig. Oral bacterial alpha diversity is associated with country of origin. (a-c) Alpha
diversity analysis (Shannon Index (a), observed OTU (b) and Chao1 (c)) from 16S rRNA gene
sequences from oral microbiota shows the difference among population from USA, RSA,
Ghana and Jamaica. USA, the United States of America; RSA, South Africa. No shared letters
above the boxplot means p< 0.05 between two groups.
(TIF)
S13 Fig. Oral bacterial alpha diversity is not associated with individual CM risk factors.
Alpha diversity analysis (Shannon Index) from 16S rRNA gene sequence data of oral micro-
biota against each CM risk factors, including waist circumference, blood pressure, blood fast-
ing glucose, triglyceride and HDL concentration in USA, RSA, Ghanaian and Jamaican
populations. USA, the United States of America; RSA, South Africa.
(TIF)
S14 Fig. Oral bacterial beta diversity is significantly different between different countries.
Principal coordinate analyses (PCoA) of weighted (a) and unweighted (b) UniFrac distances
of oral microbiota composition in USA, RSA, Ghanaian and Jamaican population. USA, the
United States of America; RSA, South Africa.
(TIF)
S15 Fig. Oral bacterial beta diversity based on weighted UniFrac distance is associated
with individual CM risk factor. (a-r), Principal coordinate analyses (PCoA) of weighted Uni-
Frac distance of oral microbiota composition against each CM risk factors, including waist
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circumference, blood pressure, blood fasting glucose, triglyceride and HDL concentration in
USA, RSA, Ghanaian and Jamaican populations. USA, the United States of America; RSA,
South Africa.
(TIF)
S16 Fig. Oral bacterial beta diversity based on unweighted UniFrac distance is associated with
individual CM risk factor. (a-r), Principal coordinate analyses (PCoA) of unweighted UniFrac
distance of oral microbiota composition against each CM risk factors, including waist circumfer-
ence, blood pressure, blood fasting glucose, triglyceride and HDL concentration in USA, RSA,
Ghanaian and Jamaican populations. USA, the United States of America; RSA, South Africa.
(TIF)
S17 Fig. Oral bacterial alpha diversity is not associated with elevated CM risk across all the
countries (except Jamaica). Alpha diversity analysis (Shannon Index) from 16S rRNA gene
sequence data of oral microbiota against elevated CM risk, defined as at least of 3 CM risk fac-
tors of waist circumference, elevated blood pressure, elevated blood fasting glucose, triglycer-
ide and HDL concentration in USA, RSA, and Ghanaian populations. CMD, elevated CM risk.
(TIF)
S18 Fig. Specific oral bacterial exact sequences variances (ESV) are differentially abundant
between populations from all countries/each country and individual CM risk factor. (a-c),
Waist circumference across all, male and female participants; (d-f), elevated blood pressure
across all, male and female participants; (g), hypertriglyceridemia across female participants;
(h) HDL concentration across male participants. Only significantly differential ESAs with rela-
tive abundance� 1% in at least one group are shown. Data shown are mean± S.E.M. p(fdr-
corrected) <0.05. USA, the United States of America; RSA, South Africa.
(TIF)
S19 Fig. Specific oral bacterial exact sequences variances (ESV) are differentially abundant
between populations from each country and individual CM risk factor. (a), Waist circum-
ference in USA, Ghanaian and RSA population; (b), elevated fasting plasma glucose in USA
population; (c), hypertriglyceridemia in Ghanaian population. Only significantly differential
ESAs with relative abundance� 1% in at least one group are shown. Data shown are mean± S.
E.M. p(fdr-corrected) < 0.05. USA, the United States of America; RSA, South Africa.
(TIF)
S20 Fig. Correlation between gut and oral microbial beta diversity of unweighted UniFrac
distances. (a) Scatter plot of beta diversity in the gut microbiota versus the oral microbiome
independently of the country of origin; (b-e) and for each country (b) USA, (c) RSA, (d),
Ghana (e) and Jamaica. USA, the United States of America; RSA, South Africa.
(TIF)
S21 Fig. Correlation between gut and oral microbial beta diversity of weighted UniFrac
distances. (a) Scatter plot of beta diversity in the gut microbiota versus the oral microbiome
independently of the country of origin; (b-e) and for each country (b) USA, (c) RSA, (d),
Ghana (e) and Jamaica. USA, the United States of America; RSA, South Africa.
(TIF)
S1 Table. Contributions of CM risk factors and participants’ characteristics to the interin-
dividual dissimilarities in gut microbial composition. USA, the United States of America;
RSA, South Africa.
(DOCX)
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S2 Table. Differential ESV abundance of gut microbiota by each CM risk including waist
circumference, blood pressure, blood fasting glucose, triglyceride and HDL concentration
in USA, RSA, Ghanaian and Jamaican population (adjusted for country, age, BMI and gen-
der across the entire cohort). USA, the United States of America; RSA, South Africa. ESV,
Exact Sequence Variant. Data shown are mean± S.E.M.
(DOCX)
S3 Table. Contributions of CM risk factors and participants’ characteristics to the interin-
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